Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease

doi:10.12092/j.issn.1009-2501.2018.04.019

Abstract

Abstract:

Coronary heart disease (CHD) is caused by genetic environmental interaction. Studies have shown that cytochrome P450 (CYP) metabolites such as epoxyeicosatrienoic acids (EETs), 20-hydroxy-eicosatetraenoic acid (20-HETE) and sex hormones play important roles in maintaining cardiovascular homeostasis. In vivo, CYP2C19 and CYP2J2 catalyze the metabolism of arachidonic acid (AA) to EETs; CYP4F2 and CYP1A1 are the main synthetases of 20-HETE; CYP17A1 and CYP19 are important synthetases of sex hormones. Therefore, polymorphism of the above CYP genes is likely to affect the development of CHD by influencing the production of its metabolites. This article reviews the five years' advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease so as to provide referential ideas for the personalized treatment of CHD.

Key words: coronary heart disease, polymorphism, cytochrome P450, susceptibility

CLC Number:

R541.4

PENG Qiuju, YAN Huacheng, SHI Lei. Advances in the relationship between cytochrome P450 SNP and susceptibility to coronary heart disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(4): 477-480.

References

［1］Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2［J］. Circulation, 2004, 110(15): 2132-2136.
［2］Tzveova R, Naydenova G, Yaneva T, et al. Gender-specific effect of CYP2C8*3 on the risk of essential hypertension in Bulgarian patients［J］. Biochem Genet., 2015, 53(11-12): 319-333.
［3］Kumar ASA, Kumar SS, Umamaheswaran G, et al. Association of CYP2C8, CYP2C9 and CYP2J2 gene polymorphisms with myocardial infarction in South Indian population［J］. Pharmacol Rep, 2015, 67(1): 97-101.
［4］Xu Y, Ding H, Peng J, et al. Association between polymorphisms of CYP2J2 and EPHX2 genes and risk of coronary artery disease［J］. Pharmacogenet Genomics, 2011, 21(8): 489-494.
［5］Xia XL,Fa BT,Cong S,et al.Research/review: Insights into the mutation-induced dysfunction of arachidonic acid metabolism from modeling of human CYP2J2［J］.Curr Drug Metab,2014, 5(5):502-513.
［6］Zhu Q, Fu Z, Ma Y, et al. A novel polymorphism of the CYP2J2 gene is associated with coronary artery disease in Uygur population in China［J］. Clin Biochem, 2013, 46(12): 1047-1054.
［7］Hokimoto S, Tabata N, Akasaka T, et al. Gender differences in impact of CYP2C19 polymorphism on development of coronary artery disease［J］. J Cardiovasc Pharmacol, 2015, 65(2): 148-152.
［8］张立国, 喻卓. CYP2C19基因多态性与云南汉族人群冠心病的相关性研究［J］. 中西医结合心脑血管病杂志, 2016, 14(14):1597-1600.
［9］Polonikov A, Kharchenko A, Bykanova M, et al. Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population［J］. Gene, 2017, 627(1):451-459.
［10］李园园, 章政, 贾秀娟,等. 细胞色素P450 2C19+681G/A多态性与冠心病发病年龄的相关性［J］. 临床心血管病杂志, 2015,31(7):739-741.
［11］Ye H,Zhou A,Hong Q,et al.Association of seven thrombotic pathway gene CpG-SNPs with coronary heart disease［J］.Biomed Pharmacother,2015,72:98-102.
［12］Cheng J, Edin ML, Hoopes SL, et al. Vascular characterization of mice with endothelial expression of cytochrome P450 4F2［J］. The FASEB Journal, 2014, 28(7): 2915-2931.
［13］Stec DE,Roman RJ,Flasch A,et al.Functional polymorphism in human CYP4F2 decreases 20-HETE production［J］.Physiol Genomics,2007,30(1):74-81.
［14］Yu C, Yan Q, Fu C, et al. CYP4F2 genetic polymorphisms are associated with coronary heart disease in a Chinese population［J］. Lipids Health Dis, 2014, 13(1): 1-5.
［15］Yang H, Fu Z, Ma Y. A novel polymorphism of the CYP4F2 gene is associated with acute coronary syndrome［J］. Heart, 2012, 98(Suppl 2): E194.
［16］赵平, 常培叶, 南景龙,等. CYP4F2基因多态性与蒙古族冠心病的相关性研究［J］. 心血管康复医学杂志, 2016(1):18-21.
［17］Taspinar M, Aydos S, Sakiragaoglu O, et al. Impact of genetic variations of the CYP1A1, GSTT1, and GSTM1 genes on the risk of coronary artery disease［J］. DNA Cell Biol, 2012, 31(2): 211-218.
［18］Zhang X, Lv S, Guo C, et al. Gene-gene interaction between PPARG and CYP1A1 gene on coronary artery disease in the Chinese Han population［J］. Oncotarget, 2017, 8(21): 34398-34404.
［19］Lakshmi SVV, Naushad SM, Saumya K, et al. Role of CYP1A1 haplotypes in modulating susceptibility to coronary artery disease［J］. Indian J Biochem Biophys, 2012, 49(5):349-355.
［20］Zhang J, Wang Y, Liu Y, et al. Lack of association between CYP1A1 T6235C polymorphism and coronary artery disease: Evidence from a meta-analysis［J］. Mol Med Rep, 2013, 7(2): 543-548.
［21］Zou JG, Ma YT, Xie X, et al. The association between CYP1A1 genetic polymorphisms and coronary artery disease in the Uygur and Han of China［J］. Lipids Health Dis, 2014, 13(1): 1-12.
［22］Schunkert H, Knig IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease［J］. Nat Genet, 2011, 43(4): 333-338.
［23］Dichgans M, Malik R, Knig IR, et al. Shared genetic susceptibility to ischemic stroke and coronary artery disease［J］. Stroke, 2014, 45(1): 24-36.
［24］Huang EW, Peng LY, Zheng JX, et al. Investigation of associations between ten polymorphisms and the risk of coronary artery disease in Southern Han Chinese［J］. J Hum Genet, 2016, 61(5): 389-393.
［25］Dai CF, Xie X, Yang YN, et al. Relationship between CYP17A1 genetic polymorphism and coronary artery disease in a Chinese Han population［J］. Lipids Health Dis, 2015, 14(1): 1-10.
［26］ Dai CF, Xie X, Ma YT, et al. Haplotype analyses of CYP17A1 genetic polymorphisms and coronary artery disease in a Uygur population［J］. J Renin Angiotensin Aldosterone Syst, 2015, 16(2): 389-398.
［27］Wang B, Fu ZY, Ma YT, et al. Identification of a CYP19 gene single-nucleotide polymorphism associated with a reduced risk of coronary heart disease［J］. Genet Test Mol Biomarkers, 2016, 20(1): 2-10.
［28］Bampali K, Grassos C, Mouzarou A, et al. Genetic variant in the CYP19A1 gene associated with coronary artery disease［J］. Genet Res Int, 2015, 2015:1-5.

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHOU Jing, ZHOU Chen, LIAO Ke, QIU Ailin, DONG Weilei, GUO Zifen. Correlation between progesterone receptor G1978T polymorphism and endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 400-406.
[4]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[5]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[6]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[7]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[8]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[9]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[10]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Evinacumab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
[11]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Inclisiran [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
[12]	WANG Qi, ZOU Yunzeng. New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
[13]	CHANG Shufu . Progress of medical treatment of coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
[14]	WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming. Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
[15]	CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177.